DKMS funds blood cancer research. Research grants each offer €240,000.
Scientists with a research focus on stem cell transplantation and cell therapy are invited to apply for the 2023 DKMS John Hansen Research Grant. The call for applications launched on 10 August; the deadline for applications is 2 December 2022.
Application criteria and further details about the DKMS John Hansen Research Grant are available on the DKMS Professionals’ Platform. If you have any questions, please email DKMS at firstname.lastname@example.org.
Through this grant, the DKMS Stiftung Leben Spenden (Foundation for Giving Life) supports up to four outstanding research projects each year that aim to advance medical progress and improve the chances of recovery for blood cancer patients. The eligibility requirements include a doctoral degree: PhD, MD or equivalent, obtained no longer than 10 years ago. The research grants are ach offering €240,000, which will be paid out over a period of three years.
Every year, more than 1.3 million people worldwide are diagnosed with blood cancer. A blood stem cell transplantation saves the lives of many of them. However, by far not all patients are permanently cured afterwards. Relapses and severe complications, especially graft-versus-host disease, still pose a great challenge for medicine and science.
DKMS is committed to medical progress beyond its original tasks as a stem cell donor centre. An important pillar of this commitment is the promotion of young scientists.
"Our goal is to help as many patients as possible, across the globe," explained Professor Dr. Marcel van den Brink, Chairman of the DKMS Medical Council.
"To achieve this goal, we must continue to develop and improve stem cell transplantation and other cellular therapies. It is therefore vital that the best research in this field is secured for the future. We are very pleased to be able to contribute towards this with the DKMS John Hansen Research Grant, which supports research by talented early career physicians and scientists."
DKMS is known as one of the world's leading stem cell donor centres. More than 11 million potential stem cell donors are registered with DKMS. To date, DKMS has already enabled more than 100,000 second chances at life. In addition, the non-profit organisation operates its own research unit in Dresden and, with the DKMS Life Science Lab, has one of the most powerful HLA typing laboratories in the world.
Since the beginning of 2020 alone, DKMS research teams have launched nine innovative scientific studies. Find out more about the scientific commitment of DKMS on the DKMS Professionals’ Platform.
John A. Hansen was an outstanding oncologist and distinguished immunogeneticist at the renowned Fred Hutchinson Cancer Research Center in Seattle.
With his excellent achievements in the field of hematopoietic stem cell transplantation, this dedicated and empathetic physician made a significant contribution to increasing the efficacy and safety of blood stem cell and bone marrow transplantations, and so gave numerous patients a second chance at life. As a long-standing member of the board of the DKMS Stiftung Leben Spenden and a member of the DKMS Medical Council, he was deeply connected to the DKMS family.
DKMS Stiftung Leben Spenden is the wholly owned parent company of DKMS gGmbH and the entire international DKMS Group.